Search Results - "HERBST, R. S"

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers by Gettinger, S. N., Choi, J., Mani, N., Sanmamed, M. F., Datar, I., Sowell, Ryan, Du, Victor Y., Kaftan, E., Goldberg, S., Dong, W., Zelterman, D., Politi, K., Kavathas, P., Kaech, S., Yu, X., Zhao, H., Schlessinger, J., Lifton, R., Rimm, D. L., Chen, L., Herbst, R. S., Schalper, K. A.

“…The biological determinants of sensitivity and resistance to immune checkpoint blockers are not completely understood. To elucidate the role of intratumoral…”
Get full text

Preoperative risk assessment does not allow to predict root filling length using machine learning: A longitudinal study by Herbst, S.R., Herbst, C.S., Schwendicke, F.

“…First we aimed to identify significant associations between preoperative risk factors and achieving optimal root filling length (RFL) during orthograde root…”
Get full text

Innovative Clinical Trials: The LUNG-MAP Study by Steuer, CE, Papadimitrakopoulou, V, Herbst, RS, Redman, MW, Hirsch, FR, Mack, PC, Ramalingam, SS, Gandara, DR

“…Although the proportion of patients with squamous cell carcinoma of the lung has declined over the last two decades, the disease is still fatal for tens of…”
Get full text

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer by Heymach, J.V., Lockwood, S.J., Herbst, R.S., Johnson, B.E., Ryan, A.J.

“…ZODIAC was a randomized phase III study of second-line treatment in patients with advanced non-small cell lung cancer (NSCLC) that evaluated the addition of…”
Get full text

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours by Kozloff, M F, Martin, L P, Krzakowski, M, Samuel, T A, Rado, T A, Arriola, E, De Castro Carpeño, J, Herbst, R S, Tarazi, J, Kim, S, Rosbrook, B, Tortorici, M, Olszanski, A J, Cohen, R B

“…Background: This phase I dose-finding trial evaluated safety, efficacy and pharmacokinetics of axitinib, a potent and selective second-generation inhibitor of…”
Get full text

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours by Martin, L P, Kozloff, M F, Herbst, R S, Samuel, T A, Kim, S, Rosbrook, B, Tortorici, M, Chen, Y, Tarazi, J, Olszanski, A J, Rado, T, Starr, A, Cohen, R B

“…Background: Axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, enhanced the efficacy of chemotherapy…”
Get full text

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer by Massarelli, E, Andre, F, Liu, D.D, Lee, J.J, Wolf, M, Fandi, A, Ochs, J, Le Chevalier, T, Fossella, F, Herbst, R.S

“…With the availability of chemotherapy agents for first- and second-line treatment of advanced non-small-cell lung cancer (NSCLC), the patient population that…”
Get full text

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors by Infante, J. R., Kurzrock, R., Spratlin, J., Burris, H. A., Eckhardt, S. G., Li, J., Wu, K., Skolnik, J. M., Hylander-Gans, L., Osmukhina, A., Huszar, D., Herbst, R. S.

“…Purpose Inhibition of kinesin spindle protein or Eg5 causes the formation of monoastral mitotic spindles, which leads to cell death. AZD4877 is a specific,…”
Get full text

Surrogate markers in antiangiogenesis clinical trials by DAVIS, D. W, MCCONKEY, D. J, ABBRUZZESE, J. L, HERBST, R. S

“…Novel antiangiogenic agents currently being developed may ultimately be more effective against solid tumours and less toxic than cytotoxic chemotherapy. As a…”
Get full text

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer by Hastings, K., Yu, H.A., Wei, W., Sanchez-Vega, F., DeVeaux, M., Choi, J., Rizvi, H., Lisberg, A., Truini, A., Lydon, C.A., Liu, Z., Henick, B.S., Wurtz, A., Cai, G., Plodkowski, A.J., Long, N.M., Halpenny, D.F., Killam, J., Oliva, I., Schultz, N., Riely, G.J., Arcila, M.E., Ladanyi, M., Zelterman, D., Herbst, R.S., Goldberg, S.B., Awad, M.M., Garon, E.B., Gettinger, S., Hellmann, M.D., Politi, K.

“…Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however,…”
Get full text

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up by Kadara, H, Choi, M, Zhang, J., Parra, E.R., Rodriguez-Canales, J., Gaffney, S.G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Yoo, Y., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D.L., Heymach, J., Kaftan, E., Townsend, J.P., Lynch, T.J., Schlessinger, J., Lee, J., Lifton, R.P., Wistuba, I.I., Herbst, R.S.

“…Lung adenocarcinomas (LUADs) lead to the majority of deaths attributable to lung cancer. We performed whole-exome sequencing (WES) and immune profiling…”
Get full text

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC by Mok, T.S.K., Lopes, G., Cho, B.C., Kowalski, D.M., Kasahara, K., Wu, Y.-L., de Castro, G., Turna, H.Z., Cristescu, R., Aurora-Garg, D., Loboda, A., Lunceford, J., Kobie, J., Ayers, M., Pietanza, M.C., Piperdi, B., Herbst, R.S.

“…We evaluated whether tissue tumor mutational burden (tTMB) and STK11, KEAP1, and KRAS mutations have clinical utility as biomarkers for pembrolizumab…”
Get full text

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial by Herbst, R.S., Baas, P., Perez-Gracia, J.L., Felip, E., Kim, D.-W., Han, J.-Y., Molina, J.R., Kim, J.-H., Dubos Arvis, C., Ahn, M.-J., Majem, M., Fidler, M.J., Surmont, V., de Castro, G., Garrido, M., Shentu, Y., Emancipator, K., Samkari, A., Jensen, E.H., Lubiniecki, G.M., Garon, E.B.

“…In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced…”
Get full text

Role of novel targeted therapies in the clinic by Herbst, R S

“…The number and variety of novel, molecular-targeted agents offers realistic hope for significant advances in cancer treatment. The potential of these new…”
Get full text

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function by Choi, M., Kadara, H., Zhang, J., Parra, E.R., Rodriguez-Canales, J., Gaffney, S.G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Kim, K., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D.L., Heymach, J., Kaftan, E., Townsend, J.P., Lynch, T.J., Schlessinger, J., Lee, J., Lifton, R.P., Herbst, R.S., Wistuba, I.I.

“…Lung squamous cell carcinoma (LUSC) accounts for 20–30% of non-small cell lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to…”
Get full text

Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis by YANO, Seiji, SHINOHARA, Hisashi, HERBST, Roy S, KUNIYASU, Hiroki, BUCANA, Corazon D, ELLIS, Lee M, DAVIS, Darren W, MCCONKEY, David J, FIDLER, Isaiah J

“…We investigated the molecular mechanisms of angiogenesis in experimental brain metastasis. Cells from six different human cancer cell lines (proven to produce…”
Get full text

Radionuclide Extraction by 2,6-Pyridinedicarboxylamide Derivatives and Chlorinated Cobalt Dicarbollide by Romanovskiy, V. N., Babain, V. A., Alyapyshev, M. Yu, Smirnov, I. V., Herbst, R. S., Law, J. D., Todd, T. A.

“…The extraction properties of diamide derivatives of dipicolinamide (2,6-pyridinedicarboxylamide or DPA, (R′R″NCO) 2 C 5 NH 3 ) in mixtures containing…”
Get full text

Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells by Yano, Seiji, Shinohara, Hisashi, Herbst, Roy S., Kuniyasu, Hiroki, Bucana, Corazon D., Ellis, Lee M., Fidler, Isaiah J.

“…We determined the molecular mechanisms that regulate the pathogenesis of malignant pleural effusion (PE) associated with advanced stage of human,…”
Get full text

PEG-400 Partitioning in the HCCD/PEG Process for Cs and Sr Recovery by Herbst, R. S., Peterman, D. R., Robinson, Troy A.

“…The properties of the chloro-protected cobalt bis(dicarbollide) anion in the acidic form (HCCD), and in the presence of polyethylene glycol (PEG-400), are well…”
Get full text

Some aspects of fundamental chemistry of the Universal Extraction (UNEX) process for the simultaneous separation of major radionuclides (cesium, strontium, actinides, and lanthanides) from radioactive wastes by Luther, T. A., Herbst, R. S., Peterman, D. R., Tillotson, R. D., Garn, T. G., Babain, V. A., Smirnov, I. V., Stoyanov, E. S., Antonov, N. G.

“…Scientists at the Idaho National Laboratory (INL) and Khlopin Radium Institute (KRI) collaboratively developed and validated the concept of a Universal…”
Get full text